Introduction
Immusante is a phytopharmaceutical formulation, recommended as an immunotherapeutic support in immunocompromised conditions such as viral infections, opportunistic infections, and chemotherapy and radiotherapy-induced neutropenia. Immusante augments immune function, attenuates disease manifestation, and improves resistance to diseases.
Composition
Each Immusante tablet contains: Exts. Shanta (Prosopis glandulosa) 150 mg Lodhra (Symplocos racemosa) 100 mg
Immusante is a phytopharmaceutical formulation, recommended as an immunotherapeutic support in immunocompromised conditions such as viral infections, opportunistic infections, and chemotherapy and radiotherapy-induced neutropenia. Immusante augments immune function, attenuates disease manifestation, and improves resistance to diseases.
Composition
Each Immusante tablet contains: Exts. Shanta (Prosopis glandulosa) 150 mg Lodhra (Symplocos racemosa) 100 mg
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $72M
Founded date: 2010
Investors 2
| Date | Name | Website |
| - | T1D Fund | t1dfund.or... |
| 17.07.2021 | ARCH Ventu... | archventur... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 14.11.2017 | Series C | $40M | ARCH Ventu... |
| 22.12.2014 | Series B | $12M | - |
| 13.12.2011 | Series A | $20M | - |
Mentions in press and media 14
| Date | Title | Description |
| 12.09.2018 | Term Sheet — Wednesday, September 12 | REBOOT REPRESENTATION Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop Melinda Gates’ Pivotal Ventures teamed up with McKinsey & Company to conduct research on tech companies’ inter... |
| 11.09.2018 | ImmusanT Receives Investment from JDRF T1D Fund | ImmusanT, Inc., a Cambridge, Mass.-based clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to translate and deliver first-in-class peptide-based immune therapies to people living with autoimmune... |
| 14.11.2017 | ImmusanT Lands $40M | CAMBRIDGE, MA, ImmusanT, a clinical-stage company developing Nexvax2 today announced the completion of a $40 million Series C equity financing. >> Click here for more funding data on ImmusanT >> To export ImmusanT funding da... |
| 14.11.2017 | ImmusanT Raises $40 Million Series C from ARCH Venture and Vatera Healthcare | CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmusanT, Inc., a clinical-stage company developing Nexvax2®, a therapeutic vaccine designed to induce immune tolerance in celiac disease, today announced the completion of a $40 million Series C equity fi... |
| 14.11.2017 | ImmusanT Raises $40M in Series C Financing | ImmusanT, Inc., a Cambridge, Mass.-based clinical-stage company developing a therapeutic vaccine designed to induce immune tolerance in celiac disease, completed a $40m Series C equity financing. Backers included ARCH Venture Partners and V... |
| 22.12.2014 | ImmusanT Raises $12M in Series B | CAMBRIDGE, MA, ImmusanT Inc. announced today it has raised $12 million in Series B financing from Vatera Healthcare Partners. >> Click here for more funding data on ImmusanT >> To export ImmusanT funding data to PDF and Exce... |
| 22.12.2014 | ImmusanT Raises $12M in Series B Financing | ImmusanT Inc., a Cambridge, Mass.-based developer of an immunotherapy for Celiac Disease, raised $12m in Series B financing. Vatera Healthcare Partners LLC made the investment. Led by Leslie Williams, president and CEO, ImmusanT develops Ne... |
| 22.12.2014 | Helping those with celiac disease tolerate gluten: ImmusanT raises $12M | The company said its adjuvant-free immunotherapy’s made up of three gluten-derived peptides in saline that are responsible for the immune reaction that causes celiac disease. “We are proud to lead the effort to build a robust clinical devel... |
| 05.09.2012 | Celiac disease immunotherapy that would replace a gluten-free diet begins clinical trials | In these patients, the body’s immune response to gluten affects the process of the small intestine and can inhibit the absorption of nutrients into the body and can potentially cause a host of deficiency complications. No medicines are avai... |
| 14.12.2011 | ImmusanT Raises $20M in Series A Financing from Vatera Healthcare Partners | ImmusanT, Inc., a Cambridge, Mass.-based biotechnology company focused on restoring tolerance to gluten in celiac disease, has raised $20m in Series A financing from Vatera Healthcare Partners LLC. The company intends to use the funding to ... |
Show more